Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases

Veterinary and Comparative Oncology

Volumn 7, Issue 3, 2009, Pages 196-206

  Cooper, Maureen ^a   Tsai, XinRu ^a   Bennett, Peter ^a  

^a Veterinary Specialist Centre   (Australia)

Author keywords

CCNU; Chemotherapy; Dog; Mast cell tumour; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; LOMUSTINE; VINBLASTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; MALE; MASTOCYTOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; FEMALE; LOMUSTINE; MALE; MASTOCYTOMA; VINBLASTINE;

CANIS FAMILIARIS;

EID: 68549132602     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2009.00190.x     Document Type: Article

References (21)

1. Thamm DH and Vail DM. 2007 Mast cell tumours. In: Small Animal Clinical Oncology 4th edn., SJ Withrow and EG MacEwan, eds., Philadelphia, WB Saunders, 2007; 402-424.
2. Murphy S, Sparkes AH, Smith KC, Blunden AS and Brearley MJ. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Veterinary Record 2004; 154: 743-746.
3. Hottendorf GH and Nielsen SW. Pathologic survey of 300 extirpated canine mastocytomas. Zentralblatt für Veterinärmedizin A 1967; 14: 272-281.
4. Patnaik AK, Ehler W and MacEwen EG. Canine cutaneous mast cell tumour: morphologic grading and survival time in 83 dogs. Veterinary Pathology 1984; 21: 469-474.
5. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. Journal of Small Animal Practice 1973; 14: 27-40.
6. Séguin B, Leibman NF, Bregazzi VS, Ogilvie GK, Powers BE, Dernell WS, Fettman MJ and Withrow SJ. Clinical outcome of dogs with grade-II mast cell tumours treated with surgery alone: 55 cases (1996-1999). Journal of the American Veterinary Medical Association 2001; 7: 1120-1123.
7. Weisse C, Shofer FS and Sorenmo K. Recurrence rates and sites for grade II canine cutaneous mast cell tumours following complete surgical excision. Journal of the American Animal Hospital Association 2002; 1: 71-73.
8. Camps-Palau MA, Liebman NF, Elmslie R, Lana SE, Plaza S, McKnight J, Risbon R and Bergman PJ. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisolone: 35 cases (1997-2004). Veterinary and Comparative Oncology 2007; 5: 156-167.
9. Hayes A, Adams V, Smith K, Maglennon G and Murphy S. Vinblastine and prednisolone chemotherapy for surgically excised grade III canine mast cell tumours. Veterinary and Comparative Oncology 2007; 5: 168-176.
10. Thamm DH, Turek MM and Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Science 2006; 6: 581-587.
11. Thamm DH, Mauldin EA and Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumours: 41 cases (1992-1997). Journal of Veterinary Internal Medicine 1999; 13: 491-497.
12. Davies DR, Wyatt KM, Jardine JE, Robertson ID and Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumours. Journal of the American Animal Hospital Association 2004; 40: 124-130.
13. Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Engler SJ and Cotter SM. Treatment of canine mast cell tumours with CCNU (lomustine). Journal of Veterinary Internal Medicine 1999; 13: 601-605.
14. Gerritsen RJ, Teske E, Kraus JS and Rutteman GR. Multi-agent chemotherapy for mast cell tumours in the dog. Vet Quarterly 1998; 20: 28-31.
15. McCaw DL, Miller MA, Ogilvie GK, Withrow SJ, Brewe WG, Klein MK, Bell FW, Anderson SK Jr. Response of canine mast cell tumors to treatment with oral prednisolone. Journal of Veterinary Internal Medicine 1994; 8: 406-408.
16. Veterinary Co-operative Oncology Group (VCOG). Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 195-213.
17. Turrel JM, Kitchell BE, Miller LM and Théon A. Prognostic factors for radiation treatment of mast cell tumours in 85 dogs. Journal of the American Veterinary Medical Association 1988; 193: 936-940.
18. Chun R, Garrett LD and Vail DM. Cancer chemotherapy. In: Small Animal Clinical Oncology 4th edn., SJ Withrow and EG MacEwan, eds., Philadelphia, WB Saunders, 2007; 172.
19. Michels GM, Knapp DW, DeNicola DB, Glickman N and Bonney P. Prognosis following surgical excision of canine cutaneous mast cell tumours with histopathologically tumor-free versus nontumor-free margins: A retrospective study of 31 cases. Journal of the American Animal Hospital Association 2002; 38: 458-466.
20. Séguin B, Faulkner Besancon M, McCallan JL, Dewe LL, Tenwolde MC, Wong EK and Kent MS. Recurrance rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumours: 28 dogs (1994-2002). Journal of Veterinary Internal Medicine 2006; 20: 933-940.
21. Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Cretin JD, Morrison-Collister K, Cotter SM and Moore AS. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs. Journal of Veterinary Internal Medicine 2004; 18: 75-80.